Drug Demonstrates Efficacy in Patients with Episodic Migraines

Amgen’s erenumab (Aimovig) achieved positive results in the first-of-its-kind phase 3b LIBERTY trial for the treatment of patients with episodic migraines who had previously failed 2 to 4 preventive treatments, according to a press release. LIBERTY is the first study to investigate a treatment targeting the calcitonin gene-related peptide (CGRP) pathway specifically in this patient population, according to the press release.

The trial included 246 patients who had experienced 2 to 4 previous preventive treatment failures. The patients were randomized to receive monthly subcutaneous injections of either erenumab 140 mg or placebo for 12 weeks.

According to the data, patients treated with erenumab had nearly 3-fold higher odds of having their migraine days cut by at least 50%. More than twice as many patients taking erenumab achieved this reduction compared with placebo.

Erenumab is currently the only investigational fully human monoclonal antibody under regulatory review that was designed to selectively block the CGRP receptor, which plays a role in migraine activation, according to Amgen.

The full story is available at SpecialtyPharmacyTimes.com.

Even more resources pertaining to headaches and migraines can be found on Pharmacy Times' new sister site, NeurologyLive.